In conclusion, we found that EZH2 inhibitors promote apoptosis in MM cell lines through the NF-κB signaling pathway and reduce TIGIT ligand CD155 expression on MM cell surfaces by inhibiting the mTOR signaling pathway. Here, TIGIT is linked to Miyoshi myopathy.